Orca T - Orca Bio
Alternative Names: Orca-T; TregCD34; TregGraft; TRGFT-201Latest Information Update: 08 Oct 2025
At a glance
- Originator Orca Bio; Stanford University
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Phase I/II Lymphoid leukaemia; Myelofibrosis